News coverage about Amphastar Pharmaceuticals (NASDAQ:AMPH) has trended somewhat positive this week, according to Accern Sentiment. The research group ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Amphastar Pharmaceuticals earned a media sentiment score of 0.20 on Accern’s scale. Accern also assigned headlines about the company an impact score of 43.471966464359 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the news headlines that may have effected Accern Sentiment’s rankings:
- $62.58 Million in Sales Expected for Amphastar Pharmaceuticals Inc (AMPH) This Quarter (americanbankingnews.com)
- Amphastar Pharmaceuticals (AMPH) Lifted to “Hold” at Zacks Investment Research (americanbankingnews.com)
- An Intrinsic Value Calculation For Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) Shows It’s 39.91% Undervalued (finance.yahoo.com)
- Amphastar Pharmaceuticals, Inc. :AMPH-US: Earnings Analysis: Q3, 2017 By the Numbers : January 1, 2018 (finance.yahoo.com)
AMPH has been the subject of a number of recent research reports. BMO Capital Markets boosted their price target on Amphastar Pharmaceuticals from $16.00 to $17.00 and gave the company a “market perform” rating in a research note on Friday, November 10th. Zacks Investment Research cut Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, October 10th. Raymond James Financial cut Amphastar Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $18.00 price objective on the stock. in a research report on Thursday, November 9th. Needham & Company LLC lifted their price objective on Amphastar Pharmaceuticals from $20.00 to $23.00 and gave the company a “buy” rating in a research report on Friday, December 1st. Finally, Jefferies Group set a $19.00 price objective on Amphastar Pharmaceuticals and gave the company a “buy” rating in a research report on Sunday, October 29th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the company’s stock. Amphastar Pharmaceuticals has an average rating of “Hold” and an average price target of $19.50.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings data on Wednesday, November 8th. The company reported $0.07 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.02 by $0.05. Amphastar Pharmaceuticals had a return on equity of 2.30% and a net margin of 0.12%. The firm had revenue of $57.90 million for the quarter, compared to analysts’ expectations of $57.23 million. During the same period in the previous year, the firm earned $0.14 EPS. The business’s quarterly revenue was down 9.8% on a year-over-year basis. sell-side analysts predict that Amphastar Pharmaceuticals will post -0.03 earnings per share for the current year.
In related news, Director Stephen B. Shohet sold 7,866 shares of the business’s stock in a transaction that occurred on Thursday, December 14th. The stock was sold at an average price of $18.87, for a total value of $148,431.42. Following the transaction, the director now directly owns 31,982 shares of the company’s stock, valued at approximately $603,500.34. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Stephen B. Shohet sold 7,862 shares of the business’s stock in a transaction that occurred on Thursday, October 12th. The stock was sold at an average price of $18.73, for a total value of $147,255.26. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 92,060 shares of company stock worth $1,716,956. Insiders own 11.10% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Amphastar Pharmaceuticals (AMPH) Earns Coverage Optimism Score of 0.20” was first reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.com-unik.info/2018/01/07/amphastar-pharmaceuticals-amph-earns-coverage-optimism-score-of-0-20.html.
Amphastar Pharmaceuticals Company Profile
Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.
What are top analysts saying about Amphastar Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Amphastar Pharmaceuticals and related companies.